12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CaPre omega-3 phospholipids: Phase II started

Neptune's Acasti Pharma Inc. subsidiary began an open-label, Canadian Phase II trial evaluating CaPre in about...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >